Price
No data yet.
Social Signal Score
Revenue
$70.60M+245.95%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Ryan Gorenstein
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 610
- Beta
- 1.24
- Country
- CA
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 13.05
Financials
Revenue
$70.60M+245.9%Net Income
$32.09M-58.8%EBITDA
$36.09MFree Cash Flow
$17.05MEPS (diluted)
$0.08-60.3%Shares Outstanding (diluted)
385.31M+2.6%Operating Expenses
$18.80MCash & Debt
$797.02MReturn of Capital
$16.36MRevenue by Segment (annual)
$146.59MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $149.15M | $-9.61M | $-0.03 |
| 2024 | $117.61M | $41.08M | $0.11 |
| 2023 | $87.24M | $-73.96M | $-0.19 |
| 2022 | $86.75M | $-168.73M | $-0.45 |
| 2021 | $64.56M | $-396.11M | $-1.07 |
| 2020 | $46.72M | $-73.14M | $-0.21 |
| 2019 | $17.84M | $1.19B | $3.76 |
| 2018 | $12.12M | $-21.64M | $-0.15 |
| 2017 | $4.14M | $2.53M | $0.02 |
| 2016 | $412.3K | $-1.20M | $-0.02 |
| 2015 | $3.40M | $278.3K | $0.01 |
| 2014 | $-665.0K | $-4.15M | $-0.15 |
| 2013 | $-213.4K | $-26.9K | $-0.05 |
| 2012 | $0.00 | $-31.2K | $-0.07 |
Valuation
CRONhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newszacks.com·23h ago·Neutral
Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock Cronos Group (CRON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
View source ↗
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $0.03 per share
Typical surprise +99.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.09 vs $0.01beat
- Mon, May 11$0.01 vs $0.01beat
- Thu, Feb 26$-0.00 vs $0.01miss
- Thu, Nov 6$0.07 vs $0.02beat
- Thu, Aug 7$-0.10 vs $-0.02miss
- Thu, May 8$0.02 vs $0.01beat
Estimates and results for CRON via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CRON officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.